Reviewing DBV Technologies (NASDAQ:DBVT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR)Defense World · Oct 17, 2026
Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New PlatformSeeking Alpha · Oct 15, 2026
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline TranscriptSeeking Alpha · Oct 14, 2026
Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT StudyMarketBeat · Oct 14, 2026
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy VolunteersBusiness Wire · Oct 14, 2026
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe HypertriglyceridemiaBusiness Wire · Oct 7, 2026Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$1.28 | -$1.36 | Miss |
| May 7, 2026 | -$1.09 | -$0.93 | Beat |
| Feb 5, 2026 | $0.60 | $0.22 | Miss |
| Nov 25, 2025 | -$0.11 | -$0.18 | Miss |
| Aug 7, 2025 | -$0.94 | -$1.26 | Miss |
| May 12, 2025 | -$0.06 | $2.75 | Beat |